How Costly is Financial (not Economic) Distress? Evidence from Highly Leveraged Transactions that Became Distressed [PDF]
This paper studies thirty-one highly leveraged transactions (HLTs) of the 1980s that subsequently became financially distressed. At the time of distress, all sample firms have operating margins that are positive and in the majority of cases greater than ...
Gregor Andrade, Steven N. Kaplan
core
Health Center Financial Check-Up: Prescriptions for Strengthening New York's Diagnostic and Treatment Centers [PDF]
, 2010 Analyzes evidence of financial distress among nonprofit health centers and contributing factors for individual centers as well as the sector. Makes recommendations for the state, philanthropic organizations, public and private payers, and health ...
core
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
The Covid-19 outbreak, corporate financial distress and earnings management. [PDF]
Int Rev Financ Anal, 2023 Aljughaiman AA +3 more
europepmc +1 more source
Can Corporate Governance Variables Enhance the Prediction Power of Accounting-Based Financial Distress Prediction Models? [PDF]
We integrated accounting, corporate governance, and macroeconomic variables to build up a binary logistic regression model for the prediction of financially distressed firms.
Lee, Tsun-Siou +2 more
core
The Deteriorating Financial Health of New York State's Health Centers [PDF]
, 2009 Summarizes findings on the breadth and depth of financial distress in 2001-07 in the health center sector. Highlights low levels of solvency, cash flow, and payments; discusses implications for primary care for the underserved; and makes ...
core
British Journal of Clinical Pharmacology, EarlyView.Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden +3 more
wiley +1 more source
Discussion of "The Asymmetric Impact of COVID-19: A Novel Approach to Quantifying Financial Distress across Industries". [PDF]
Eur Econ Rev, 2023 Wang X.
europepmc +1 more source
Zuranolone: A case study in (regulatory) rush to judgement?
British Journal of Clinical Pharmacology, EarlyView.Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove +4 more
wiley +1 more source
Examining financial distress of the Vietnamese listed firms using accounting-based models. [PDF]
PLoS One, 2023 Tran T +4 more
europepmc +1 more source